The interleukin-1 receptor antagonist (IL-1Ra) is an endogenous protein that can prevent the binding of IL-1 to its cellsurface receptors. Among a number of techniques for gene transfer in vivo, the direct injection of naked DNA into muscle is simple, inexpensive and safe. In this study, we evaluated the potential of intramuscular gene therapy with plasmid DNA containing the cDNA for IL-1Ra in the prevention of murine collagen-induced arthritis (CIA). DBA/1 mice were immunized with bovine type II collagen. At 4 weeks after the initial immunization, expression plasmid for IL-1Ra was injected into four selected sites in the thigh and calf muscles of DBA/1 mice. Control mice received the same plasmid, but lacking the IL-1Ra coding sequence. Macroscopic analysis of paws for redness, swelling and deformities showed that the onset of moderate to severe CIA in the paws of mice injected with IL-1Ra DNA was significantly prevented (Po0.05). In addition, both the synovitis and the cartilage erosion in knee joints were dramatically reduced in mice treated with IL-1Ra DNA (Po0.05). The expression of IL-1b was significantly decreased in the ankle joints of mice treated with IL-1Ra (Po0.01). Interestingly, the levels of IL-1Ra in sera and joints after intramuscular injection of IL-1Ra DNA were significantly lower than when protein had been used in previous reports, suggesting that the therapeutic effect may be achieved by an alternative mechanism(s) rather than by systemic elevation of IL-1Ra. These observations provide the first evidence that direct intramuscular injection of expression plasmid for IL-1Ra may effectively suppress the inflammatory pathology in arthritis.
Introduction
Rheumatoid arthritis (RA) is a chronic disease characterized by inflammation of the joints with concomitant destruction of cartilage and bone. 1 Although the causes of RA are not fully understood, various experimental and clinical studies suggest that proinflammatory cytokines, particularly interleukin-1 (IL-1) among others, have an important role in RA pathogenesis. [2] [3] [4] [5] The IL-1 receptor antagonist (IL-1Ra) is a natural protein that competitively inhibits the binding of IL-1b and IL-1a to IL-1 receptor types I and II in humans and various animals, and improves the inflammatory symptoms of arthritis in experimental animal models. 1, [6] [7] [8] [9] [10] Several independent clinical trials have been completed in which the recombinant IL-1Ra protein has been administered for a long-term period to patients with RA. 11, 12 The results indicate that treatment with IL-1Ra lowers the levels of proteins involved in the acute phase of RA and the counts of swollen joints and, furthermore, may inhibit radiographic progression of the disease. 12, 13 Recently, the use of recombinant human IL-1Ra protein was approved for the treatment of human RA. However, owing to its short half-life in vivo, the recombinant protein has to be administrated continously. [14] [15] [16] [17] Effective control of autoimmune arthritis requires prolonged neutralization of proinflammatory mediators, and gene therapy offers several potentially unique advantages over previous protein therapies. With the recent advances in gene therapy, the IL-1Ra gene has been delivered by retrovirus-based, adenovirusbased and adeno-associated virus (AAV)-based vectors into synoviocytes to achieve anti-inflammatory effects both in vivo and in vitro with a varying degree of success. 8, 9, [18] [19] [20] Among various viral and nonviral techniques for gene transfer in vivo, the direct injection of naked DNA into muscle is probably the simplest, most inexpensive and safest. 21 We previously showed that gene transfer into cardiac or leg muscles by direct injection of plasmid DNA in vivo can be used to deliver cytokines efficiently. 22, 23 In the present study, we applied this method for the delivery of IL-1Ra in a murine collagen-induced arthritis (CIA) model. Plasmid vector encoding the human IL-1Ra gene was introduced into the muscles of arthritic mice, and its effect on arthritis was measured by macroscopic evaluation of paws, determination of the level of IL-1 and histologic findings in synovium and cartilage.
Results
Level of IL-1b was increased in CIA in mice CIA in mice is an autoimmune type of arthritis which shows many characteristics in common with human RA. 24, 25 Onset of arthritis in DBA/1 mice occurs 4-6 weeks after the first immunization with type II collagen and is dependent on the expression of TNF-a and IL-1. 15, 26, 27 To be certain about our CIA model, we examined the level of IL-1b in knee joints and sera of normal and CIA mice using the commercially available ELISA kit. CIA was induced by immunizing mice with bovine type II collagen, followed by boosting with the same antigen. At 40 days after the initial immunization, mice that had macroscopic signs of arthritis were selected and compared with healthy mice. As shown in Figure 1 , a significant increase in the level of IL-1b was observed in knee joints of mice with CIA as compared with that of healthy mice (Po0.0001). However, the serum concentration of IL-1b in both normal and CIA mice was less than 3 pg/ml, the detection threshold of the assay (data now shown). These data indicated that CIA mice display marked upregulation of IL-1b in joints accompanied by synovial growth similar to human RA.
1,2,4
Intramuscular gene therapy using IL-1Ra DNA inhibits CIA in mice As a plasmid expression vector for intramuscular gene therapy, we used pCK, which has been shown to drive a high level of gene expression in the skeletal and cardiac muscles of mice. 22, 23 The human IL-1Ra coding sequence was cloned to pCK, resulting in pCK-IL-1Ra (Figure 2a) . The expression of human IL-1Ra was confirmed by transfecting 293T cells with pCK-IL-1Ra and determining IL-1Ra by ELISA. As shown in Figure 2b , 800 ng/ml of IL-1Ra was produced from 1 Â 10 5 of 293T cells transfected with pCK-IL-1Ra, while less than 22 pg/ml was detected in the same number of cells transfected with the control plasmid (Po0.001).
We tested whether the intramuscular transfer of the plasmid DNA containing the cDNA for human IL-1Ra could be used to prevent experimental arthritis. At 4 weeks after the initial immunization, mice that had one or two limbs with mild (¼ index 1) macroscopic signs of arthritis were selected and divided into four groups. In two groups, 100 or 400 mg of pCK-IL-1Ra was injected into four sites in the skeletal muscles of each mouse (n ¼ 15), respectively. As a control, saline solution alone or saline solution containing the same amount of a control plasmid lacking the IL-1Ra coding sequence, pCK, was used for the other two groups of mice (n ¼ 15), respectively. The incidence of arthritis in the paws was assessed by macroscopic examination such as joint swelling and erythema every 3-5 days until 30 days after treatment. As shown in Figure 3 , the incidence of moderate to severe arthritis (Zindex 2) in the paws of mice treated with 400 mg of IL-1Ra DNA was significantly reduced when compared with those of mice treated with saline or control DNA at every time point except on day 3 (Po0.05). When 100 mg of IL-1Ra DNA was injected, statistically significant therapeutic effects were obtained only on day 10 following treatment. These results suggested that intramuscular injection of IL-1Ra DNA efficiently prevented the occurrence of moderate to severe arthritis in a dose-dependent manner. With this result, 400 mg of DNA was chosen for the later experiment.
The effects of 400 mg of IL-1Ra DNA on the CIA were confirmed by a separate experiment. As shown in Figure  4a , the increase of paw thickness was significantly smaller in mice treated with pCK-IL-1Ra, as compared with that in mice treated with the control plasmid 30 Figure 1 Significant increase in the level of mIL-1b in the knee joints of mice with CIA. Aqueous joint extracts were isolated from joint tissues and analyzed using ELISAs for mIL-1b. Data for mIL-1b are the mean7s.e.m. of 10 tissue samples. *Po0.0001 versus normal mice. (Figure 4b ). At 30 days after DNA injection, the incidence of moderate to severe arthritis (Zindex 2) was seen in 94% of the paws of those mice that had received control vector DNA, while it was only seen in 56% of the paws of those mice that had been treated with IL-1Ra DNA (Po0.05) ( Figure  4c ). These results clearly showed that intramuscular injection of IL-1Ra DNA could efficiently reduce the incidence of murine CIA and that under our experimental system, therapeutic effects of a single injection last for a minimum of 30 days following treatment.
Delivery of IL-1Ra DNA by intramuscular injection decreased the severity of synovitis and cartilage erosion
We also assessed the incidence of arthritis in the knee joints by histological examination 12 days after treatment. Sections stained with hematoxylin and eosin showed that synovial proliferation and inflammatory cell infiltration were significantly decreased in the knee joints of mice treated with IL-1Ra DNA, as compared with those of mice injected with a control plasmid (Figure 5a and b). Comparison of the histological grades of synovitis between the IL-1Ra DNA-treated group and the control group showed that the difference was statistically significant (Po0.05) ( Figure 5c ). When IL1Ra DNA was injected, thinning and hyalinization of the cartilage were also inhibited ( Figure 6 ). Safranin Ostaining of proteoglycan in the cartilage showed that the proteoglycan was well preserved in the joints of mice treated with IL-1Ra DNA, but not in the joints treated with control plasmid DNA (Figure 6a and b) . A statistically significant difference was found in the severity of cartilage erosion between the IL-1Ra DNAtreated group and the control groups (Po0.05) ( Figure  6c ). These results demonstrated that intramuscular injection of IL-1Ra DNA efficiently reduced the degree of histopathologic changes in the knee joints of CIA mice.
Effects of IL-1Ra DNA transfer on the level of IL-1b in the ankle joints
First, we tested whether the level of proinflammatory cytokine IL-1b could be used as an index of arthritis. As shown in Figure 7a , there is a very significant correlation between the level of IL-1b in the paw and the macroscopic index of the paws in the murine CIA model. High levels of IL-1b (higher than 10 ng/g of tissue protein) were detected in 86.5% of the paws with high macroscopic scores (Zindex 2), while in less than 14% of the paws with index 1. This result indicated that the level of IL-1b in the paws could be used as a marker for the severity of CIA. We then examined the effects of intramuscular delivery of the IL-1Ra gene on the level of IL-1b in the paws of mice. Consistent with the joint swelling result, high levels of IL-1b (higher than 10 ng/g of tissue protein) were found in 45% of the paws of mice receiving control plasmid, versus 23% of the paws of mice treated with IL-1Ra DNA (Po0.01) (Figure 7b ). There was a statistically significant difference in the average levels of IL-1b in the paws between the IL-1Ra-treated group and those of the control group (Po0.01) (Figure 7c ). These results suggested that IL-1Ra gene delivery by intramuscular injection could efficiently reduce the levels of IL-1b in murine CIA.
In vivo expression of IL-1Ra after intramuscular injection of IL-1Ra DNA
The results of the experiments described above showed that intramuscular injection of IL-1Ra DNA could have an anti-inflammatory effect on all joints of the treated mice. One simple explanation for this systemic therapeutic effect of intramuscular gene therapy is that the systemic level of IL-1Ra was elevated to a therapeutically sufficient level after intramuscular IL-1Ra gene transfer. To explore such a possibility, we examined the levels of Figure 3 Effects of IL-1Ra DNA on the occurrence of arthritis in CIA. Mice were immunized with bovine type II collagen on day 0. On day 28, mice received intramuscular injection of 100 or 400 mg of pCK-IL-1Ra, or 400 mg of pCK or saline solution, respectively (n¼15). The occurrence of moderate to severe arthritis (Zindex 2) in paws was evaluated by macroscopic scoring as described in Materials and methods. *Po0.05 versus pCK (Fisher's exact test).
IL-1Ra DNA injection inhibits CIA J-M Kim et al IL-1Ra in the injected muscles, sera and knee joints of C57Bl/6 mice after intramuscular injection of IL-1Ra DNA. As shown in Figure 8a , significant levels (higher than 3.5 mg/g of total protein) of IL-1Ra were detected in the injected areas of skeletal muscles for 20 days after DNA injection (Po0.05, compared with pCK). Serum IL1Ra concentration gradually increased after intramuscular injection and reached its peak at 750 pg/g of total protein on day 15, while that of control mice similarly treated with the pCK vector was less than 1 pg/g of total protein, the detection threshold of the assay (Figure 8b) . We obtained similar results by using nonarthritic and arthritic DBA/1 mice (data not shown). Although the serum IL-1Ra levels of treated mice were significant as compared with those of the control mice (Po0.05, compared with pCK), the value was much lower than the level of IL-1Ra known to be required to get a therapeutic effect in recombinant protein study. We also examined the level of IL-1Ra in the knee joints of mice 15 days after intramuscular injection when the level of IL1Ra in the injected muscle areas and sera reached its peak. There was no difference in the level of human IL1Ra between the IL-1Ra DNA-treated mice and control mice (data not shown). These results indicated that the therapeutic effect of intramuscular IL-1Ra gene transfer is not achieved by elevation of systemic IL-1Ra and that an alternative mechanism may be involved.
Discussion
The findings of the present study demonstrate that intramuscular injection of expression plasmid for human IL-1Ra could reduce the incidence of moderate to severe CIA and that the therapeutic effects last for 30 days after a single treatment. It further indicates that intramuscular injection of IL-1Ra DNA reduces the level of IL-1b in the joints of treated CIA mice.
IL-1 appears to be an important mediator of inflammation in RA. [2] [3] [4] [5] It is well known that IL-1 can stimulate monocytes, recruit inflammatory cells and induce secretion of factors that degrade cartilage. 28 In animal studies, systemic administration of IL-1 has been found to accelerate the development of CIA. 29 IL-1 is present in the synovial fluid of patients with RA and in RA synovium. 30, 31 Consistent with previous reports, our data showed that the level of IL-1 is upregulated in the knee joints of mice with CIA. These observations, together with the report that the blocking of IL-1 activity with anti-IL-1 monoclonal antibody protects against CIA, suggest that IL-1 may play an important role in the inflammatory process of RA. 15, 27 IL-1 activity in vivo appears to be regulated by IL-1Ra, a natural inhibitor of IL-1. Administration of human IL1Ra has been shown to inhibit the development of CIA. Although a relatively low dose of recombinant IL-1Ra (3-30 mg/day) was effective in the preventive model of murine CIA, 14 sustained high blood levels of IL-1Ra, such as by continuous administration or osmotic pumping system, were required to obtain a complete suppression of all aspects of the disease. 15, 17 The efficacy of recombinant human IL-1Ra in the treatment of active RA was confirmed in long-term placebo-controlled clinical studies. 11, 12 Recently, recombinant human IL-1Ra protein was approved for the treatment of active RA. However, because of the chronic characteristics of autoimmune arthritis, daily subcutaneous injection of 100 mg IL-1Ra is generally required to obtain a clinically significant benefit.
The present study indicated that intramuscular injection of plasmid DNA containing the cDNA encoding IL1Ra could reduce not only the incidence of CIA but also the levels of IL-1b in joints of treated mice. It has been Figure 4 Effects of IL-1Ra DNA on the disease progression in CIA. Mice were immunized with bovine type II collagen on day 0. On day 28, mice received intramuscular injection of 400 mg of pCK (n¼15) or pCK-IL-1Ra (n¼15). Joint swelling of paws was evaluated by determination of increase in paw thickness (a) and graded on a relative scale of 0-4 (b). The Z2 score was considered as incidence of moderate to severe arthritis (c). *Po0.05 versus control (Mann-Whitney rank-sum test). **Po0.05 versus control (Fisher's exact test).
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reported that the production of IL-1b was increased by IL-1b itself and other cytokines whose expressions are induced by IL-1b. 32, 33 Therefore, it is likely that intramuscular transfer of IL-1Ra DNA could efficiently block the IL-1b-mediated inflammatory signaling. With previous reports showing that intramuscular injection of expression plasmid DNA for TGF-b and soluble CR1 receptor could effectively inhibit the development of arthritis, 34, 35 the present study suggested that gene therapy for RA using the intramuscular gene delivery with a plasmid vector might be a therapeutically plausible form of RA treatment. This direct DNA transfer method has several advantages over viral vectors. 21 A large quantity of highly purified plasmid DNA can be IL-1Ra DNA injection inhibits CIA J-M Kim et al readily obtained at a relatively low cost, and gene transfer can be repeated without apparent immunological responses to the plasmid DNA vector. Furthermore, quality control of DNA production, an important step on an industrial scale, is expected to be much less complicated than other viral vectors.
In this study, we showed that single injection of plasmid DNA drives significant levels of human IL-1Ra in the injected areas of muscles, but not in knee joints. Although the serum IL-1Ra level after DNA injection was significant when compared with those of control mice, it is not likely that this level of human IL-1Ra in serum is sufficient to prevent CIA. Therefore, it remains to be elucidated how the intramuscular injection of expression plasmid for IL-1Ra can reduce the incidence of CIA without achievement of a therapeutically sufficient blood level of IL-1Ra. One possible explanation for this observation is that some cells like dendritic cells might be transfected by intramuscular injection of plasmid DNA and these cells might then migrate and play a certain role(s) in the control of disease progression. Similar to our observation, it was reported that a contralateral therapeutic effect was achieved even though significant levels (41 ng/ml) of soluble TNFa receptor or IL-1Ra were not detected in animal fluids by ELISA. 36, 37 It was suggested that certain kinds of transduced cells might play an important role(s) in contralateral therapeutic effects. 36 Furthermore, it was also reported that dendritic cells could be transfected by intramuscular injection of plasmid DNA and that the transfected dendritic cells could modulate the immune responses. 38 The possibility of genetic modification of bystander cells around the injection site of naked DNA is now being investigated.
The present study showed that the levels of IL-1Ra in the injected muscles and sera peaked on day 15 and then gradually decreased. One possible explanation for this decrease is the gradual degradation of exogenously added DNA as time progresses. 39, 40 Immune response to IL-1Ra may also contribute as the human gene was used in this study. Indeed, it was already reported that repeated injections of the human IL-1Ra (hIL-1Ra) protein could induce the antibody response to hIL-1Ra in CIA mice, although the antibody response to hIL-1Ra did not inhibit the therapeutic effects of the injected protein.
14 Further investigation into the mechanism involved in the decrease in the level of transgene expression will help to develop a new strategy for long-term gene expression by naked DNA.
To our knowledge, these results provide the first demonstration that intramuscular gene therapy with expression plasmid for the IL-1Ra can be used to modulate the disease process in an animal model of arthritis, without elevation of systemic levels of IL-1Ra. Certainly, further investigation into the exact mechanism responsible for the observed therapeutic effect by intramuscular injection of IL-1Ra DNA is in order.
Materials and methods
Cloning of human IL-1Ra and construction of expression vector cDNA encoding human IL-1Ra was cloned from total RNA prepared from human peripheral blood lymphocytes by reverse transcription (RT) -polymerase chain reaction (PCR). PCR primers were 5 0 -AAGCTTATG GAAATCTGCAGAGGCCTCCGCAGTCAC-3 0 and 5 0 -GTCGACCTACTCGTCCTCCTGGAAGTAGAATTTGGT-3 0 . The amplified cDNA was initially cloned into the pGEM7Zf(+) plasmid (Promega, WI, USA). Following sequence confirmation, the human IL-1Ra cDNA was cloned into the HindIII site of the mammalian expression vector pCK, which has been previously described, 22 resulting in the pCK-IL-1Ra. 23 The pCK-IL-1Ra plasmid was purified using an EndoFree plasmid Maxi prep kit (Qiagen,Valencia, CA, USA), dissolved in 0.9% NaCl, diluted to 4 mg/ml and stored at -201C before use.
Induction of CIA and treatment protocol DBA/1 mice (Jackson Laboratory, Maine, USA), aged 9-10 weeks at the start of experiments, were immunized intradermally at the base of the tail with bovine type II collagen (100 mg; Chondrex, WA, USA) emulsified in Freund's complete adjuvant (GIBCO BRL, NY, USA). 41 On day 21, the animals were boosted with an intradermal injection of 100 mg type II collagen emulsified in Freund's incomplete adjuvant (GIBCO BRL, NY, USA). Gradual onset of arthritis normally starts approximately 4 weeks after initial immunization. In this study, mice that had one or two paws with mild (¼ index 1) macroscopic signs of arthritis were chosen at 4 weeks after the initial immunization. These mice were divided and treated with an indicated amount of expression plasmid for the IL-1Ra, control plasmid or the same volume of saline. For each mouse, four different sites in the thigh and calf muscles of two hind legs received direct injections with plasmid DNA with the use of a 1-ml syringe and a 27-gauge needle (100 mg/25 ml at each of four sites, for a total of 400 mg/100 ml for each mouse or 25 mg/25 ml at each of four sites, for a total of 100 mg/100 ml for each mouse).
Macroscopic scoring of CIA
Paws were individually scored by macroscopic system ranging from 0 to 4, as previously described, with a maximum score of 4 for each paw: 0 ¼ normal; 1 ¼ detectable arthritis with erythema; 2 ¼ significant swelling and redness; 3 ¼ severe swelling and redness from joint to digit; and 4 ¼ maximal swelling and deformity with ankylosis. 42 The thickness of each paw was also measured using a spring-load caliper. Scoring of arthritic index and measuring of the paw thickness were done by two independent observers who were blinded with regard to the experimental groups.
Histologic processing and analysis of knee joints
Knee joints were dissected, fixed in 10% phosphatebuffered formalin for 2 days, decalcified in 10% EDTA for 7 days, and then embedded in paraffin. Standard frontal sections of 7 mm were prepared, stained with either hematoxylin/eosin or Safranin O/fast green. Histopathological changes were scored using the following parameters. The severity of synovitis (synovial proliferation and inflammatory cell infiltration) was scored using a four-point scale (0-3, where 0 is normal and 3 severe). 43 Cartilage destruction was separately graded on a scale from 0 to 4 for each joint, where 0 ¼ normal, 1 ¼ dead chondrocyte, 2 ¼ local destruction of superficial chodrocyte, 3 ¼ multifocal destruction of chondrocyte/subchondral bone, 4 ¼ complete destruction of chondrocyte and massive destruction of subchondral bone. Scoring was performed on decoded slides by two observers, as previously described. 44 
Measurement of IL-1Ra and IL-1b
The levels of human IL-1Ra in the injected areas of muscles and serum and the levels of murine IL-1b in knees and ankles were measured using commercially available ELISA for human IL-1Ra (R&D Systems, Minniapolis, MN, USA) and mIL-1b (R & D Systems), according to the manufacturer's recommendations. Briefly, the injected areas of muscles were excised and homogenized in lysis buffer (25 mM Tris-HCl pH 7.4, 50 mM NaCl, 0.5% Na-deoxycholate, 2% NP-40, 0.2% SDS, protease inhibitors). In the case of joint tissues, whole mice knees or ankles were snap frozen in liquid nitrogen and were ground into powder by pestle, then lysed with the lysis buffer. The supernatants containing total protein were used to measure the levels of cytokines. In the case of serum, it was directly subjected to IL-1Ra assays without any pretreatment. The levels of IL-1Ra and mIL-1b were normalized to the total amount of protein prepared from tissue lysates, as measured by way of a DC protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA).
Statistical analysis
Differences between experimental group were tested using the Mann-Whitney rank-sum test, unless stated otherwise. P-values less than 0.05 were considered significant.
